Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05260957
Title CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lazaros Lekakis

Burkitt lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

primary mediastinal B-cell lymphoma

B-cell lymphoma


Mosunetuzumab + Polatuzumab vedotin-piiq

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.